Mutual of America Capital Management LLC acquired a new position in shares of Enovis Co. (NYSE:ENOV – Get Rating) during the second quarter, Holdings Channel.com reports. The institutional investor acquired 39,274 shares of the company’s stock, valued at approximately $2,160,000.
A number of other large investors have also recently bought and sold shares of the company. M&T Bank Corp acquired a new stake in Enovis during the 2nd quarter worth approximately $137,000. Boenning & Scattergood Inc. bought a new position in Enovis during the 2nd quarter worth approximately $210,000. Connor Clark & Lunn Investment Management Ltd. bought a new position in Enovis during the 2nd quarter worth approximately $261,000. TAGStone Capital Inc. bought a new stake in shares of Enovis in the 2nd quarter valued at $288,000. Finally, Citadel Investment Advisory Inc. bought a new stake in shares of Enovis in the 2nd quarter valued at $288,000. 89.40% of the stock is currently owned by institutional investors and hedge funds.
Insider Activity at Enovis
In related news, EVP Daniel A. Pryor sold 67,421 shares of the business’s stock in a transaction dated Tuesday, November 15th. The stock was sold at an average price of $54.58, for a total value of $3,679,838.18. Following the sale, the executive vice president now directly owns 75,731 shares in the company, valued at approximately $4,133,397.98. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. 8.30% of the stock is currently owned by company insiders.
Wall Street Analyst Weigh In
Enovis Stock Performance
Shares of Enovis stock opened at $54.99 on Thursday. Enovis Co. has a 52-week low of $43.88 and a 52-week high of $151.63. The stock’s 50-day simple moving average is $49.81 and its 200 day simple moving average is $55.28. The stock has a market capitalization of $2.98 billion, a P/E ratio of 114.56, a P/E/G ratio of 1.15 and a beta of 2.03.
Enovis Corporation operates as a medical technology company worldwide. It develops, manufactures, and distributes medical device products used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals to treat patients with musculoskeletal conditions resulting from degenerative diseases, deformities, traumatic events, and sports related injuries.
- Get a free copy of the StockNews.com research report on Enovis (ENOV)
- Institutional Support for Analog Devices Remains High
- Microsoft Shares: Is it Time to Back Up the Truck?
- Is the 60/40 Portfolio Mix Still in Vogue?
- Salesforce Cuts Labor, Shows Strong Earnings Despite Challenges
- Three CBD Stocks to Dominate a Budding Industry
Receive News & Ratings for Enovis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enovis and related companies with MarketBeat.com's FREE daily email newsletter.